...
首页> 外文期刊>Analytical methods >Simultaneous determination of urinary quinolinate, gentisate, 4-hydroxybenzoate, and α-ketoglutarate by high-performance liquid chromatography-tandem mass spectrometry
【24h】

Simultaneous determination of urinary quinolinate, gentisate, 4-hydroxybenzoate, and α-ketoglutarate by high-performance liquid chromatography-tandem mass spectrometry

机译:高效液相色谱-串联质谱法同时测定尿中喹啉酸酯,龙胆酸酯,4-羟基苯甲酸酯和α-酮戊二酸酯

获取原文
           

摘要

Renal cell carcinoma (RCC) remains a difficult-to-detect cancer for which new detection methodologies are urgently needed to improve screening efficacy. Urinary metabolomic profiling has identified several potential RCC biomarkers, including quinolinic acid, 4-hydroxybenzoic acid, gentisic acid and ?±-ketoglutaric acid. These four endogenous metabolites have unique pathophysiological mechanisms associated with RCC, suggesting that they may be promising biomarkers for earlier RCC detection. However, the lack of targeted analytical methods for their simultaneous determination in urine has hindered efforts to evaluate their clinical applicability. In this study, a robust high-performance liquid chromatography -tandem mass spectrometry (HPLC-MS/MS) technique using multiple reaction monitoring was developed to simultaneously monitor these four urinary biomarkers. The method was validated by multiple figures of merit including method detection limits (0.05 ng mLa?’1 to 1 ng mLa?’1), spiked recovery accuracy (88.6a€“114.8%) and reproducibility (0.4a€“9.3% RSD). The applicability of the method was further demonstrated in clinically relevant 100-fold diluted urine specimens. All four potential biomarkers were successfully quantified with urinary concentrations that were in agreement with previous reports. In conclusion, an accurate and sensitive method has been described for the simultaneous determination of quinolinic acid, 4-hydroxybenzoic acid, gentisic acid and ?±-ketoglutaric acid. We anticipate this method to significantly benefit clinical translational research aiming to evaluate the clinical applicability of these four potential biomarkers.
机译:肾细胞癌(RCC)仍然是一种难以检测的癌症,迫切需要新的检测方法来提高筛查效率。尿代谢组学分析已鉴定出几种潜在的RCC生物标志物,包括喹啉酸,4-羟基苯甲酸,龙胆酸和α±酮戊二酸。这四种内源性代谢物具有与RCC相关的独特病理生理机制,表明它们对于早期RCC检测可能是有希望的生物标志物。然而,缺乏用于尿液中同时测定的靶向分析方法,阻碍了评估其临床适用性的努力。在这项研究中,开发了一种强大的高效液相色谱-串联质谱(HPLC-MS / MS)技术,该技术使用了多个反应监测功能,可以同时监测这四个尿液生物标志物。该方法已通过多项质量指标验证,包括方法检测限(0.05 ng mLa?'1至1 ng mLa?'1),加标回收率准确度(88.6a“ 114.8%”)和重现性(0.4a€“ 9.3%RSD) )。该方法的适用性在临床相关的100倍稀释尿液样本中得到了进一步证明。所有四种潜在的生物标志物均已通过尿液浓度成功定量,与先前的报告一致。总之,已经描述了一种同时测定喹啉酸,4-羟基苯甲酸,龙胆酸和α±酮戊二酸的准确而灵敏的方法。我们预计该方法将大大有益于临床转化研究,旨在评估这四种潜在生物标记物的临床适用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号